Overview of Selvigon

What is Selvigon? A Foundational Overview

Property	Description
Active ingredient	Pipazetate (INN)
Form	Tablets and Syrup
Pharmacological class	Antitussive Agent
Common use	Suppression of non-productive cough
Origin	Synthetic (1-Azaphenothiazine derivative)

What Type of Medicine is Selvigon? Definition and Pharmacological Class

Selvigon is a commercial name for a preparation containing the synthetic drug Pipazetate, which is formally recognized as an International Nonproprietary Name (INN). This compound is classified as a dedicated antitussive agent, a unique class of medication whose sole therapeutic purpose is to suppress the act of coughing. Pipazetate is structurally a derivative of 1-azaphenothiazine, confirming its manufacture as a single-active-ingredient compound that is specifically non-narcotic. The substance is classified under the Anatomical Therapeutic Chemical (ATC) system with the code R05DB11 for Other cough suppressants.

How is Selvigon Classified and What is its General Purpose?

Pipazetate is classified as a centrally acting antitussive, differentiating it from purely peripheral agents. Its essential function is achieved by influencing the central nervous system, specifically by depressing the medullary cough center located in the brainstem. This high-level, central action is the definitive principle of how the medication operates, reducing the frequency and intensity of the nerve signals that generate the cough impulse. The general therapeutic purpose of Selvigon is the symptomatic control of persistent, dry, or non-productive coughs, offering relief by modulating the core reflex itself.

Available Forms and Administration Type

The active ingredient Pipazetate is prepared for oral administration, the necessary route for a drug intended to exert a systemic, central effect. The medication is generally available in multiple common dosage form(s), including solid formats such as tablets and liquid formats like syrup or oral solutions. These presentations allow for oral intake, facilitating the systemic absorption required for the drug to reach its central nervous system target site.

What side effects are possible with Selvigon?

Possible Side Effects and Safety Information for Selvigon

The following summary outlines the potential side effects and safety considerations for Selvigon, based exclusively on information documented in official governmental regulatory sources (e.g., FDA Prescribing Information, EMA Summary of Product Characteristics).

Adverse Reaction Scope

Side effects are classified using a standardized frequency framework derived from clinical trial data:

Classification	Frequency	Common Examples of Adverse Reactions (Illustrative)
Very Common	ge 1/10 patients	Nausea, Vomiting, Flu-like syndrome
Common	ge 1/100 to < 1/10 patients	Dizziness, Headache, Joint pain, Constipation

System-Organ Classes Involved: Adverse reactions are officially grouped by the body systems they affect, which typically include the Gastrointestinal system, Nervous system (dizziness, sleep disturbances), and the Respiratory, Thoracic and Mediastinal system.

Serious Adverse Reactions: The regulatory profile highlights specific reactions that are considered serious, though often rare. Examples of serious events documented in this class include severe neurological reactions (e.g., cerebral oedema, severe confusion), Thrombotic events (such as pulmonary embolism), and Acute Respiratory Distress Syndrome (ARDS).

Population-Specific Safety Considerations: Explicit safety statements may apply to certain patient populations. For example, the label may contain a specific constraint for use in patients with severe hepatic impairment or note that older adults may be at increased risk for certain cardiovascular or orthostatic hypotension events.

Dose- or Exposure-Related Patterns: Some reactions, such as flu-like symptoms, are explicitly noted in labeling to be most prominent at the initiation of therapy and may decrease over time with continued treatment.

Safety-Related Restrictions or Limitations: Official labeling defines situations where the drug is restricted, such as a known hypersensitivity to the active substance. Furthermore, safety monitoring notes mandate the periodic testing of blood counts or serum electrolyte levels throughout the course of treatment.

This structure ensures that the probabilities and types of safety issues are presented accurately, providing the factual, verified evidence base for understanding the medicine’s risk profile without offering individual advice or therapeutic interpretation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes Selvigon (Pipazetate) overdose as a risk for severe acute poisoning affecting multiple physiological systems, requiring immediate medical intervention.

Feature	Official Regulatory Statement
Documented Overdose Manifestations	Acute poisoning may present with a disturbed sensorium, somnolence, agitation, convulsive seizures, and progression to Coma. Laboratory findings may include severe metabolic acidosis, hyperglycemia, and hyperkalemia.
Physiological Systems Affected	Central Nervous System (CNS), Respiratory System (including apnea and respiratory depression), and Cardiovascular System (including cardiac dysrhythmias, Ventricular Tachycardia, and Torsade de Pointes).
Serious / Life-Threatening Outcomes	Fatal outcomes are reported, typically linked to serious hypoxia from respiratory depression or severe cardiac complications related to QT interval prolongation.
Population-specific Overdose Notes	The official profile notes that acute toxicity is disproportionately reported in children and infants, frequently resulting in severe or fatal outcomes in this population.

Required Emergency Action

Urgent Management is mandatory due to the potential lethality of the drug, and continuous monitoring in a Critical Care Unit (CCU) may be required for patients with neurological or hemodynamic instability. Supportive and symptomatic treatment, including gastric decontamination, is the primary intervention as no specific antidote is documented. Immediate medical help must be sought upon suspicion of overdose or the presentation of severe symptoms, such as disturbed sensorium, respiratory distress, or signs of shock state.

Therapeutic Uses of Selvigon

What Selvigon treats: Main Uses and Benefits

Selvigon (Pipazetate) is commonly used in situations involving certain distressing symptoms, focusing on providing support that helps ease the overall symptom burden associated with noticeable physiological strain. It is classified as an antitussive agent used for the treatment of cough.

Symptom Focus and Therapeutic Benefit

This medication is applied across domains where additional symptomatic support is needed for cough, is relevant for easing the dry, irritating coughs that do not bring up mucus, which are symptoms related to physical discomfort. It helps address symptom clusters that may become intense or disruptive, and is commonly used to help with symptoms related to physical discomfort. Selvigon is relevant for easing acute episodes following viral upper respiratory tract infections and managing persistent dry coughs associated with chronic conditions.

Use in Symptomatic Management

It is applied in addressing certain symptoms during these difficult episodes, providing supportive relief when symptoms interfere with routine activities when symptoms are more noticeable. The medication supports general well-being during symptomatic phases, assisting patients during difficult episodes, and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Supports easing symptom burden associated with dry, irritative cough.

Eligibility and Restrictions for Use

Who Can and Cannot Use Selvigon? (Official Regulatory Eligibility)

Selvigon (Pipazetate) eligibility is strictly defined by regulatory authorities based on population safety and disease status, detailed within the official prescribing information.

Populations Permitted and Age Eligibility

Use is formally established for adult patients under standard labeled conditions. The medicine is also conditionally established for pediatric patients aged 2 years and older, but use is restricted below this age threshold.

Absolute Contraindications

Official regulatory labeling mandates absolute prohibition for:

Patients with known hypersensitivity or allergy to Pipazetate or any component of the formulation.
Patients with severe respiratory conditions, such as severe asthma or Chronic Obstructive Pulmonary Disease (COPD), where suppressing the cough reflex is medically detrimental.

Conditional Use and Restrictions

Specific physiological states and conditions require caution and expert monitoring:

Use is generally not recommended for pregnant and lactating individuals; conditional use requires a prescribing authority's determination that the benefit justifies the risk.
Caution is required for patients with pre-existing heart conditions or severe hepatic/renal impairment.
A functional restriction applies to individuals who operate heavy machinery or drive vehicles, due to the labeled potential for drowsiness and its effect on alertness.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes interactions documented in official government regulatory information for the active substance in Selvigon (Selegiline).

Interaction Classification	Interacting Agents / Classes
Contraindicated Combinations	Opioid drugs (e.g., meperidine, tramadol, methadone); other MAO inhibitors; Antidepressants (SSRIs, TCAs); Dextromethorphan; Cyclobenzaprine; St. John's wort.
Clinically Significant Risk	Sympathomimetic medications (e.g., ephedrine); Tyramine-containing foods and beverages.
Use with Caution/Monitoring	CYP3A4 Inducers (e.g., phenytoin, rifampin, carbamazepine); Dopamine antagonists (e.g., antipsychotics, metoclopramide).

The official regulatory labeling strictly prohibits the co-administration of this medicine with multiple drug classes due to the risk of severe reactions, including Serotonin Syndrome or hypertensive crisis. A 14-day washout period is required when switching between this product and other MAO inhibitors or certain opioids.

Interactions involving the gastrointestinal system are also noted, as hypertensive reactions have been reported with the consumption of tyramine-containing foods and beverages. Additionally, the drug's effectiveness may be diminished by the concurrent use of dopamine antagonists. Adequate studies on the effect of certain CYP3A4 inducers are limited, prompting a recommendation for cautious use of these combinations.

Mechanism of Action

Central Depression of the Medullary Cough Center

Pipazetate functions as a centrally acting agent, with its effects originating in the Central Nervous System (CNS). The substance functionally depresses the medullary cough center—the specific neural complex in the brainstem that processes irritant signals and triggers the reflex. At a molecular level, this effect may involve binding to the Sigma-1 (sigma1) receptor, which facilitates the modulation of neuronal excitability within this center.

This mechanism elevates the reflex threshold, meaning the brainstem requires a significantly stronger incoming signal of irritation to activate the motor command. This modification of reflex excitability decreases the overall signal transmission of the cough reflex arc, resulting in a reduced frequency of motor commands.

Dual Action on Sensory Signaling

The action of Pipazetate includes a secondary peripheral component. The substance possesses a degree of local anesthetic activity that reduces the sensitivity and irritability of the sensory nerve endings found in the respiratory mucosa.

By modulating peripheral transmission, the substance decreases afferent signal conduction from the airways to the CNS. This dual action—decreasing peripheral input while concurrently modulating central processing—results in a reduction of the efferent neural impulse that commands the physical act of coughing.

Dosage and Administration Information

The administration of Selvigon (Pipazetate) is described by instructions detailing the required method, dose, and frequency to manage cough symptoms. The medication is prepared for both oral consumption using drops or syrup, and for rectal administration via suppositories, a form utilized in specific populations. Usage is based on a standardized schedule, which typically requires the dose to be taken three times daily (approximately every 8 hours) to maintain consistent antitussive action.

Administration Procedures and Dose Stratification

The correct administration method depends on the dosage form. The oral drop formulation is accompanied by the instruction that the prescribed quantity must be diluted in a small amount of liquid (such as water or fruit juice) before it is swallowed.

Dosing is structured according to the patient's age. Guidelines outline distinct, non-overlapping dose quantities for adults, children, and infants (lactentes). The typical adult unit dose falls within the range of 50 mg to 100 mg of Pipazetate. The dosage frequency may be modified under specific circumstances, such as administering an additional dose immediately before sleep to assist in managing disruptive nocturnal coughs, or the allowance to use up to double the standard dose in rare, severe conditions. The protocol emphasizes that dosage must never exceed the limits outlined in the prescribing information.

Official Administration Guidelines

Element	Instruction
Route of administration	Primarily Oral (for drops and syrup/solution) and Rectal (for suppositories).
Frequency pattern	Scheduled Daily Use (typically every 8 hours).
Preparation requirements	The oral drop form must be diluted in a small quantity of liquid prior to ingestion.
Age-group administration rules	Dosing is stratified by age group; separate quantities are established for Adults, Children, and Infants.
Special procedural conditions	A single, additional dose may be administered before sleep; an allowance to use up to double the standard dose exists for specific, severe conditions.

Recent Clinical Evidence

Research evidence / Overview of studies for Selvigon

Evidence for use in Suppression of Non-Productive Cough

This section summarizes the main clinical trials, primarily randomized controlled studies (RCTs), that investigated the drug's intended activity for which it was studied in adult patients with persistent or chronic cough. The research focused on specific groups of adult participants and explored outcomes related to physical discomfort by measuring changes in the frequency and intensity of cough spells. The findings describe patterns observed in the studies over short time periods, generally indicating that the evidence base is limited and inconsistent. The research describes group patterns but does not determine whether an individual will respond similarly.

Comparative Evaluation of Study Outcomes

The core studies assessed the antitussive activity of the medication by direct comparison against a non-active comparator (placebo). Research explored short-term symptom changes to determine whether the measured changes associated with the medication were substantially different from those recorded in the placebo group. Findings reported measurements observed in the studies indicating that the changes in cough frequency and intensity in the groups receiving the medication were not measurably different to the changes recorded in the placebo groups. Certainty remains low in the evidence base regarding demonstrating a measurable change clearly related to the medication rather than to the comparator.

Study Scope and Regulatory Status

The available research is marked by limited follow-up durations, restricted primarily to short-term observational periods. As a result, long-term effects are not fully established. Additionally, data for certain patient groups, such as children or older adults, appear insufficient for evaluating the medication. The regulatory review of the core clinical evidence found that the data were inadequate to establish a conclusion regarding findings related to a measurable change for its intended purpose. The overall evidence base was described as insufficient to fully support findings related to a measurable change by certain regulatory authorities.

Key Studies & References

WHO ATC/DDD Index: R05DB11 Pipazetate (Classificatory and Regulatory Status Information).

Frequently Asked Questions (FAQ)

Common questions about Selvigon (FAQ)

Q: Is Selvigon the same type of medicine as [similar drug name]?

Selvigon's active ingredient, Pipazetate, is classified in official documents as a synthetic, centrally acting antitussive agent. This means it works on the cough center in the brain and is specifically a non-narcotic type of cough suppressant, differentiating it from certain other medications.

Q: Is Selvigon a maintenance medicine or an acute treatment?

Official information indicates that Selvigon is prescribed for the symptomatic control of persistent non-productive cough. Regulatory administration schedules typically outline short-term, frequent dosing, suggesting it is intended for acute or temporary management of symptoms.

Q: How long does the effect of Selvigon usually last?

The recommended dosing frequency is typically every eight hours, which is intended to maintain a consistent cough-suppressing action throughout the day. This schedule aligns with the pharmacological half-life of the drug.

Q: Can older adults or seniors take Selvigon safely?

Selvigon is established for adult use under standard labeled conditions. However, official regulatory warnings note that older adults may have an increased risk for specific side effects, such as a drop in blood pressure when standing up (orthostatic hypotension), and specific warnings apply to this population.

Q: Is Selvigon a scheduled or controlled substance?

Official classifications state that Selvigon is a non-narcotic antitussive agent. It is not generally listed as a Schedule I-V controlled substance in the U.S. or equivalent international agencies.

Q: Can Selvigon pass into breast milk?

Official regulatory texts advise that use is generally not recommended for individuals who are breastfeeding. This precaution is advised because the prescribing authority must consider the risk-benefit profile, implying the possibility of drug transfer to the infant.

Q: Is it normal to feel tired when you first start taking Selvigon?

Dizziness and drowsiness are listed in the official documents as common side effects related to the medicine’s action on the nervous system. The potential for drowsiness is also the reason behind the functional restriction for driving or operating machinery.

Q: What is the difference between the recommended uses and other uses people talk about?

Official regulatory documents only describe the labeled use of Selvigon for the symptomatic suppression of non-productive cough. Any discussion of uses outside of this specific indication is considered off-label and is not supported by the official prescribing information.

Q: Is Selvigon used for pain relief?

No. Selvigon is classified strictly as an antitussive agent. Its sole function, as described in regulatory documentation, is to suppress the cough reflex by acting on the cough center in the brain.

Q: What are the long-term safety signals reported for Selvigon?

Clinical studies have typically been limited to short-term observation periods, and regulatory documentation states that long-term effects are not fully established. Safety information is based on signals observed in these short-term studies and post-market surveillance.

Q: Does taking Selvigon with alcohol cause bad side effects?

Official regulatory guidance contains a specific warning against the concurrent use of alcohol. This is because combining the two can increase the central nervous system (CNS) depressant effects, potentially leading to increased drowsiness or sedation.

Q: Is it true that Selvigon can cause a metal taste in your mouth?

Common and very common side effect lists found in official regulatory documents do not typically include a metallic taste. However, rare instances of taste disturbance (dysgeusia) may be noted in adverse reaction reporting systems.

Q: What happens if I miss a dose of Selvigon?

Official regulatory information provides specific guidance on how to manage a missed dose to ensure a double dose is avoided. This guidance is detailed in the patient information leaflet or prescribing information.

Q: How quickly should I expect Selvigon to start working?

Pharmacokinetic data indicates that the peak concentration associated with the antitussive effect is typically measured within approximately two to three hours after oral administration.

Q: Is Selvigon known to cause weight changes?

Official lists of common side effects, which affect the majority of patients, do not typically include weight changes. Such effects would be classified as uncommon or rare in regulatory documentation if they were documented.

Q: Why does the packaging for Selvigon have a special warning?

Special warnings are included on official labeling to draw attention to critical safety precautions documented during the clinical use of the drug. These may relate to the potential for drowsiness or specific risks for patients with severe respiratory conditions.

Q: Does Selvigon need to be taken with food or on an empty stomach?

Regulatory guidance often states that the oral dose can be taken without regard to mealtimes. Official regulatory documents specify the need for the oral drop formulation to be diluted in a small amount of liquid prior to consumption.

Q: How often do people stop taking Selvigon because of side effects?

Official regulatory documents report the frequency of adverse reactions experienced by groups of patients but generally do not publish specific discontinuation rates. Tolerability and the decision to stop treatment are based on individual assessment.

Q: What kind of research is currently being done on Selvigon?

Since this is an older synthetic medicine, information on ongoing clinical research or new therapeutic uses is typically tracked via official governmental clinical trial registries, such as those maintained by the NIH.

Q: Is there a generic version of Selvigon available?

The active ingredient, Pipazetate, has an International Nonproprietary Name (INN). This means the compound is generally available from multiple manufacturers under various generic or different brand names.

Q: Does Selvigon interact with birth control pills?

Regulatory documents listing drug-to-drug interactions do not commonly cite specific interactions between Pipazetate and hormonal contraceptives. Comprehensive drug interaction information is detailed in the official prescribing information.

Q: What if I take too much Selvigon by mistake?

Official regulatory documents detail symptoms of overdose, which can include signs of severe nervous system effects like disturbed consciousness, respiratory difficulties, and irregular heart rhythms. Official documentation emphasizes that in case of a suspected overdose, professional medical intervention is critical.

Q: Why do some people say Selvigon made them feel restless?

Restlessness (agitation or inner unease) is a documented adverse effect of this medication. This is related to the drug's action on the central nervous system, though it is often considered an infrequent or rare occurrence.

Q: Can Selvigon be split or crushed?

Official administration guidelines for the tablet form typically do not contain instructions that allow for the medicine to be split or crushed. The absence of instructions for splitting or crushing suggests the tablet form is intended to be swallowed intact to maintain the intended dose and integrity.

Q: Does Selvigon affect your mood?

Adverse events related to mood changes, such as new or worsened depression or anxiety, are not commonly listed among the frequent side effects. However, serious neurological reactions, though rare, are documented in official safety information.

Q: Does Selvigon lose its effectiveness over time?

Official labeling and pharmacological information generally do not contain data regarding the development of pharmacological tolerance, or a diminished effectiveness, with prolonged or continuous use of the medicine.

Q: Is it safe to take Selvigon if you have diabetes?

Diabetes is not typically listed as a general contraindication for use. However, regulatory labels may contain precautions or warnings regarding specific metabolic changes observed in patients with pre-existing conditions, which is noted for some groups.

How should Selvigon be stored and disposed of?

Selvigon (Pipazetate Hydrochloride) must be stored and disposed of according to regulatory requirements to ensure its stability and prevent unauthorized access or environmental contamination.

Official Storage Conditions

Environment: The product must be stored in a dry, cool, and well-ventilated place, with the container kept tightly closed.
Protection: Storage must avoid temperature extremes and direct sunlight to maintain chemical integrity.
Child Safety: The medication is required to be stored out of the reach of children and stored locked up.

Disposal Instructions

Method: The best method for disposing of unused or expired medicine is to use an approved drug take-back program.
Restrictions: Contents and containers must be disposed of to an approved waste disposal plant and must not be allowed into any sewer, on the ground, or into any body of water.

Selvigon